Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-12-19
2004-12-21
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S076000
Reexamination Certificate
active
06833385
ABSTRACT:
Compounds of formula:
wherein R
1
is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in U.S. Pat. No. 4,024,175 and its divisional U.S. Pat. No. 4,087,544. The uses disclosed are: protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The compounds are useful in geriatric patients. The patents are hereby incorporated by reference.
SUMMARY OF THE INVENTION
The instant invention is a compound of Formula I and II
wherein A, X, Y, Z, W, and n are as described below.
The compounds of the invention and their pharmaceutically acceptable salts and the prodrugs of the compounds, are useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis.
The invention is also a pharmaceutical composition of a compound of Formula I or II.
The invention also includes novel intermediates useful in the preparation of the final products.
REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 0446097 (1991-02-01), None
patent: 2722192 (1994-07-01), None
patent: 119936 (1996-05-01), None
patent: 9913907 (1999-03-01), None
Keenan et al., “Imidazole-5-acrylic Acids: Potent Nonpeptide Angiotensl II Receptor Antagonists Designed Using a Novel Peptide Pharmacophore Model”,Journal of Medicinal Chemistry, American Chemical Society, vol. 35, No. 21, 1992, pp 3858-3872.
Floyd, “Prostaglandins and Congeners, 18, Synthesis of Cyclopentenolone Precursors to Prostaglandins from 2,5-Dihydro-2,5-dimethoxyfurans”,Journal of Organic Chemistry, vol. 43, No. 9, 1978, pp 1641-1643.
Brown, et al., Isocytosine H2-receptor histamine antagonist II. Synthesis and evaluation of biological activity at histamine H1-and H2-receptors of 5-(heterocyclyl) methylisocytosines,European Journal of Medicinal Chemistryvol. 24, 1989, pp 65-72.
Climent, et al., “Ba(OH)2 as Catalyst in Organic Reactions. 20. Structure-Catalytic Activity Relationship in the Wittig Reaction”,Journal of Organic Chemistry, vol. 54, 1989, pp 3695-3701.
PCT International Search Report—PCT/US00/11397.
Ganjeizadeh Mehdi
Shameem Golam M M
Warner-Lambert & Company
LandOfFree
3-heteroarylalkyl substituted GABA analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-heteroarylalkyl substituted GABA analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-heteroarylalkyl substituted GABA analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3271851